Tackling early morbidity and mortality in myeloma: assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections

niversity of Birmingham (UK)0 个研究点目标入组 977 人开始时间: 2011年8月10日最近更新: 2019年12月10日

适应症

试验速览

•1. Aged minimum of 21 years and able to give informed consent
•2. Patient with newly diagnosed symptomatic myeloma based on internationally agreed criteria, within 7 days of starting a programme of anti-myeloma therapy (or within 14 days of starting anti-myeloma therapy if already on a broad spectrum antibacterial agent)
•3. Provision of written informed consent
•4. Male or female participants

•1. Patients with contraindication to Levofloxacin:
•1.1. Known to have sensitivity/allergy to Levofloxacin or other quinolones
•1.2. Patients with a history of tendon disorders related to fluoroquinolone administration
•1.3. Patients receiving other prophylactic antibiotic treatment (excluding pneumocystis prophylaxis if regarded as essential)
•1.4. Patients receiving amiodarone or arsenic trioxide
•1.5. Patients on active antiepileptic treatment
•2. Women of childbearing age who are not willing to use appropriate methods of contraception to prevent pregnancy or women that are breastfeeding
•3. Patient thought to have mandatory requirement for prophylactic antibiotics
•4. Patient who is not going to receive anti myeloma therapy

发起方

niversity of Birmingham (UK)